AM 630;6-IODO-2-METHYL-1-[[2-(4-MORPHOLINYL)ETHYL]-1H-INDOL-3-YL](4-METHOXYPHENYL)METHANONE;SC-200365(AM-630);1-[2-(Morpholin-4-yl)ethyl]-2-Methyl-3-(4-Methoxybenzoyl)-6-iodoindole;(6-iodo-2-Methyl-1-(2-Morpholinoethyl)-1H-indol-3-yl)(4-Methoxyphenyl)Methanone;AM630;AM 630;AM-630;Methanone, [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-;Iodopravadoline (AM630)
AM630 is a selective CB2 receptor antagonist (Ki = 31.2 nM) with 165-fold selectivity over CB1 receptors; it activates TRPA1 channels in trigeminal (TG) sensory neurons and modulates TRPV1/TRPA1 signaling; it inhibits osteoclastogenesis in a dose-dependent manner in the presence of RANKL and Ti particles; it blocks CB2 receptor-mediated responses induced by CP-55,940; and it exhibits anxiolytic effects in vivo by increasing time spent in the light box in animal behavioral tests.